Aspire Biopharma (NASDAQ:ASBP) Releases Earnings Results

Aspire Biopharma (NASDAQ:ASBP) announced its quarterly earnings data on Friday. The company reported ($0.04) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $0.00 million for the quarter.

Aspire Biopharma Trading Up 1.0%

Shares of ASBP traded up $0.00 during trading hours on Friday, reaching $0.11. The stock had a trading volume of 540,844,021 shares, compared to its average volume of 19,533,442. The company has a market cap of $5.27 million, a P/E ratio of -0.23 and a beta of 0.76. Aspire Biopharma has a 52 week low of $0.09 and a 52 week high of $15.80. The company’s 50-day moving average is $0.34.

Institutional Trading of Aspire Biopharma

An institutional investor recently raised its position in Aspire Biopharma stock. Jane Street Group LLC increased its holdings in shares of Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP) by 625.8% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 152,552 shares of the company’s stock after purchasing an additional 131,533 shares during the period. Jane Street Group LLC owned 0.31% of Aspire Biopharma worth $41,000 as of its most recent filing with the SEC. 19.17% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on ASBP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a research report on Wednesday, October 8th. Wall Street Zen downgraded Aspire Biopharma to a “strong sell” rating in a report on Saturday, July 26th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat.com, Aspire Biopharma has a consensus rating of “Sell”.

About Aspire Biopharma

Aspire Biopharma Holdings, Inc, early-stage biopharmaceutical company, engages in developing and marketing of disruptive technology for delivery mechanisms for do no harm drugs in the United States. The company provides Sublingual Aspirin Product, which addresses cardiology emergencies and pain management.